Skyrizi patent expiry?

What happens when the Skyrizi patent expires?

Skirizi, also known as risankizumab, is a biologic drug developed by AbbVie for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. According to DrugPatentWatch.com [1], the US Skyrizi patent expiry is expected to occur in 2034.

Will biosimilars enter the market before then?

AbbVie has been sued by several companies, including Amgen and Fresenius Kabi, for attempting to bring biosimilars of Skyrizi to market before the patent expiry. This has led to a legal battle surrounding the patent validity and expiration dates.

Why is the patent litigation relevant to the expiry date?

The patent litigation may impact the expected date of expiry, as a successful challenge could potentially shorten the patent term. However, if the patent is upheld, the company will retain exclusivity until the listed expiry date of 2034 [1].

How will the patent expiry affect the market?

Upon patent expiry, AbbVie's market dominance for Skyrizi is likely to be disrupted by the entry of biosimilars. Biosimilars can offer reduced prices, potentially challenging the market share of Skyrizi. Additionally, other companies may develop new treatments for these indications, further expanding the market.

What are the implications for patients and healthcare systems?

The patent expiry and subsequent entry of biosimilars may lead to increased competition, potentially reducing prices and improving patient access to treatments. However, the introduction of new treatments may also lead to increased complexity in treatment decisions for healthcare providers.

References:

[1] DrugPatentWatch.com: Skirizi (risankizumab) patent information [accessible at: https://www.drugpatentwatch.com/drugs/risankizumab]